SURUNKALI BUYRAK KASALLIGIDA ANEMIYA: PATOGENEZ, DIAGNOSTIKA VA DAVOLASH SAMARADORLIGI
DOI:
https://doi.org/10.5281/zenodo.18312251Keywords:
surunkali buyrak kasalligi, anemiya, eritropoetin yetishmovchiligi, temir tanqisligi, eritropoezni rag‘batlantiruvchi vositalar, gemodializ, ferritin, transferrin to‘yinganligi, surunkali yallig‘lanish, yurak-qon tomir asoratlariAbstract
Surunkali buyrak kasalligi (SBK) jarayonida rivojlanadigan anemiya eng muhim klinik va prognostik omillardan biri bo‘lib, u bemorlarning hayot sifati pasayishiga, yurak-qon tomir asoratlarining kuchayishiga hamda kasallikning tezkor progressiyasiga olib keladi. Mazkur holatning patogenezi murakkab va ko‘p omilli bo‘lib, asosan buyrak parenximasida eritropoetin sintezining pasayishi, temir almashinuvi buzilishi, surunkali yallig‘lanish jarayonlari, gemodializ jarayonida qon yo‘qotilishi hamda eritrotsitlarning yashash davomiyligi qisqarishi bilan izohlanadi. Anemiyaning SBK bosqichlariga mos ravishda rivojlanishi uning erta aniqlanishi va differensial diagnostikasini muhim ahamiyatga ega qiladi. Diagnostik jarayonda umumiy qon tahlili, zardob ferritini, transferrin to‘yinganlik darajasi, C-reaktiv oqsil, eritropoetin miqdori hamda buyrak funksiyasini baholovchi biokimyoviy ko‘rsatkichlar kompleks tarzda o‘rganilishi zarur.
References
Abdukahharova D.A. Surunkali buyrak kasalligi va anemiya. Toshkent: Samarqand davlat tibbiyot universiteti nashriyoti, 2021. – 112 b.
Aliev M.T., Rustamov K.H. Nefrologiya asoslari. Toshkent: Tibbiyot nashriyoti, 2019. – 256 b.
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279–335.
National Kidney Foundation. KDOQI Clinical Practice Guidelines for Anemia in CKD. Am J Kidney Dis. 2012;60(5):850–886.
McClellan W.M., Aronoff S.L., Bolton W.K. Anemia in Chronic Kidney Disease: Pathophysiology and Management. N Engl J Med. 2004;351:1801–1812.
Stauffer M.E., Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.
Locatelli F., Aljama P., Barany P., et al. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1–ii47.
Babayeva S.A. Surunkali buyrak kasalligi bilan og‘rigan bemorlarda anemiya klinikasi. Buxoro: Buxoro tibbiyot instituti nashriyoti, 2018. – 98 b.
Fishbane S., Spinowitz B. Anemia in chronic kidney disease: new insights. Blood Rev. 2018;32:23–32.
Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098.
Yuldasheva N.T., Karimov S.B. Nefrologiya va buyrak kasalliklarida davolash yondashuvlari. Toshkent: Medpress, 2020. – 214 b.
Vanholder R., Massy Z., Argiles A., et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20:1048–1056.
KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis. 2005;45:S1–S153.
Goodkin D.A., Bieber B.A., Bragg-Gresham J.L., et al. Hemoglobin variability in hemodialysis patients: associations with mortality. Kidney Int. 2005;68:1330–1337.
Locatelli F., Covic A., Eckardt K.U., et al. Anaemia management in patients with chronic kidney disease: European Renal Best Practice recommendations. Nephrol Dial Transplant. 2013;28:1346–1359.
Levin A., Djurdjev O., Barrett B. Anemia in CKD: pathophysiology and treatment. Kidney Int. 2007;72:131–140..
